Accelerate Diagnostics Inc (AXDX) : Oracle Investment Management Inc scooped up 394,207 additional shares in Accelerate Diagnostics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 6,037,747 shares of Accelerate Diagnostics Inc which is valued at $129,992,693.Accelerate Diagnostics Inc makes up approximately 23.77% of Oracle Investment Management Inc’s portfolio.
Other Hedge Funds, Including , Arrowpoint Asset Management boosted its stake in AXDX in the latest quarter, The investment management firm added 151,509 additional shares and now holds a total of 619,265 shares of Accelerate Diagnostics Inc which is valued at $13,332,775. Accelerate Diagnostics Inc makes up approx 0.26% of Arrowpoint Asset Management’s portfolio.Nuveen Asset Management boosted its stake in AXDX in the latest quarter, The investment management firm added 90,030 additional shares and now holds a total of 710,571 shares of Accelerate Diagnostics Inc which is valued at $15,298,594. Accelerate Diagnostics Inc makes up approx 0.09% of Nuveen Asset Management’s portfolio. Fmr sold out all of its stake in AXDX during the most recent quarter. The investment firm sold 390,000 shares of AXDX which is valued $8,396,700. Thompson Davis added AXDX to its portfolio by purchasing 125 company shares during the most recent quarter which is valued at $2,621.
Accelerate Diagnostics Inc opened for trading at $22 and hit $22.04 on the upside on Thursday, eventually ending the session at $22, with a gain of 0.55% or 0.12 points. The heightened volatility saw the trading volume jump to 2,48,116 shares. Company has a market cap of $1,127 M.
Accelerate Diagnostics Inc. is an in-vitro diagnostics company providing solutions to improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The Company is focused on reducing the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to approximately five hours rather than the two to three days required to deliver identification and susceptibility results. It has developed a diagnostic platform the Accelerate ID/AST System (the ID/AST System) intended for the rapid diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST) which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. Accelerate Diagnostics UK Limited is a subsidiary of the Company.